Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00744042 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00744042 is a Phase 1 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 11 participants.
The verdict
NCT00744042, a Phase 1 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This clinical trial studies the safety and efficacy of asfotase alfa in infants and young children with infantile onset HPP.
Interventions
- BIOLOGICAL asfotase alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00744042
The ClinicalTrials.gov registry entry for NCT00744042 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which asfotase alfa is the first listed.
NCT00744042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00744042 about?
NCT00744042 is a clinical study titled "Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)". This clinical trial studies the safety and efficacy of asfotase alfa in infants and young children with infantile onset HPP.
What is the current status of trial NCT00744042?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2008-09. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00744042?
The interventions under investigation include: asfotase alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00744042?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.